Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5003Neoplasms 4197Prostatic Neoplasms 2428Carcinoma, Non-Small-Cell Lung 2264Colorectal Neoplasms 2052Lung Neoplasms 1705Multiple Myeloma 1459Lymphoma 1405Leukemia, Myeloid, Acute 1381Neoplasm Metastasis 1373Melanoma 1270Pancreatic Neoplasms 1200Leukemia 1196Ovarian Neoplasms 1192Lymphoma, Non-Hodgkin 1132Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091Head and Neck Neoplasms 1056Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 897Colonic Neoplasms 895Brain Neoplasms 876Stomach Neoplasms 855Recurrence 852Carcinoma, Hepatocellular 846Glioblastoma 841Lymphoma, Large B-Cell, Diffuse 771Rectal Neoplasms 759Uterine Cervical Neoplasms 728Carcinoma, Renal Cell 705Hodgkin Disease 698

Interventions

soybean oil, phospholipid emulsion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Interventional × Pena Shokeir syndrome, type 1 × Clear all
NCT04555044 2023-12-27

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

Baxter Healthcare Corporation

Phase 4 Completed
101 enrolled 29 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡